RecruitingNCT04947657

The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study

Correlation Of CoAGulation Biomarkers and Atrial Fibrillation Burden in Patients Post Catheter Ablation: the COAG-AF Pilot Study

Sponsor

Tulane University

Enrollment

20 participants

Start Date

Sep 22, 2021

Study Type

OBSERVATIONAL

Conditions

Atrial Fibrillation

Summary

The aim of the Correlation Of CoAGulation-Atrial Fibrillation (COAG-AF) study is to prove that an increase in pro-thrombotic biomarkers in AF is associated with an increase in AF burden. Secondary objectives of the study are the following: * To investigate the impact of catheter ablation on serum pro-thrombotic biomarkers in patients with AF. * To correlate coagulation biomarkers with imaging features such as, the degree of fibrosis found on Late Gadolinium Enhancement Magnetic Resonance Imaging (LGE-MRI) scans, which is a part of standard of care. * To determine baseline values of coagulation and pro-thrombotic biomarkers in the AF population and compare those baseline values with the general population values. * To compare central and peripheral thrombotic biomarkers in patients with atrial fibrillation.

Eligibility

Min Age: 18 YearsMax Age: 120 Years

Inclusion Criteria4

Patients, male or female and older than 18 years of age.
Patients diagnosed with persistent or paroxysmal AF.
Patients that are undergoing catheter ablation at Tulane University Medical Center.
Patients that had a cardiac MRI prescribed by their physician as part of their standard of care.

Exclusion Criteria12

Patients with coagulation disorders such as, von Willebrand disease, hemophilia, Immune Thrombocytopenic Purpura, etc.
Patients who are pregnant or breast-feeding or plan to become pregnant during the study period.
Are not surgically sterile.
Are of childbearing potential and are unwilling to practice two acceptable methods of birth control.
Do not plan to continue practicing two acceptable methods of birth control throughout the trial (highly effective methods of birth control are defined as those, used alone or in combination, that result in a low failure rate i.e. less than 1% per year when used consistently and correctly).
Patients with mental and/or physical ailments which may prohibit them from actively participating in the study.
Any health-related gadolinium/MRI contraindications (e.g. allergy to gadolinium, pacemakers, Implantable Cardioverter Defibrillators (ICD's), other devices/implants contraindicated for use of MRI, etc.)
Patients who have a known terminal illness with a prognosis less than 12 months at the time of the informed consent process.
Planned cardiovascular intervention.
Patient with diagnosed acute or chronic severe kidney disease or with a low glomerular filtration rate (GFR), \<30 mL per minute per 1.73 m2
Patients who cannot read, speak, and/or understand English.
Patients with cognitive impairments who are unable to give informed consent.